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Abstract
Background: To perform a comprehensive study on the relationship between vitamin D metabolism and the response to
interferon-a-based therapy of chronic hepatitis C.
Methodology/Principal Findings: Associations between a functionally relevant polymorphism in the gene encoding the
vitamin D 1a-hydroxylase (CYP27B1-1260 rs10877012) and the response to treatment with pegylated interferon-a (PEG-IFN-
a) and ribavirin were determined in 701 patients with chronic hepatitis C. In addition, associations between serum
concentrations of 25-hydroxyvitamin D3 (25[OH]D3) and treatment outcome were analysed. CYP27B1-1260 rs10877012 was
found to be an independent predictor of sustained virologic response (SVR) in patients with poor-response IL28B genotypes
(15% difference in SVR for rs10877012 genotype AA vs. CC, p=0.02, OR=1.52, 95% CI=1.061–2.188), but not in patients
with favourable IL28B genotype. Patients with chronic hepatitis C showed a high prevalence of vitamin D insufficiency
(25[OH]D3,20 ng/mL) during all seasons, but 25(OH)D3 serum levels were not associated with treatment outcome.
Conclusions/Significance: Our study suggests a role of bioactive vitamin D (1,25[OH]2D3, calcitriol) in the response to
treatment of chronic hepatitis C. However, serum concentration of the calcitriol precursor 25(OH)D3 is not a suitable
predictor of treatment outcome.
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Introduction
Chronic hepatitis C is one of the most serious infectious diseases
worldwide [1]. Less than 50% of all patients infected with hepatitis
C virus (HCV) genotype 1 and 4 as well as ,80% of those infected
with genotype 2 and 3 can be cured with a combination therapy of
pegylated interferon-a (PEG-IFN-a) and ribavirin [2]. The
adjunction of directly acting antivirals (DAA), namely the NS3-
4A protease inhibitors telaprevir and boceprevir, results in
substantially increased rates of sustained virologic response
(SVR) in both treatment-naı ¨ve and treatment-experienced patients
infected with HCV genotype 1 [3–7]. However, such triple
therapy regimens are burdened with additional adverse events and
their efficacy in prior null-responders (,2 log10 reduction in HCV
RNA after 12 weeks of PEG-IFN-a and ribavirin) remains limited
[7,8]. Therefore, despite enormous progress, there is still a need to
optimize IFN-a-based (or IFN-a-free) treatment regimens for
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ing, for example, on-treatment viral kinetics and IL28B genotype)
to select appropriate treatment regimens for individual patients
remains highly relevant [9–15]. The importance of host genetics in
the prediction of treatment outcome has been impressively
demonstrated by the discovery of the IL28B locus as determinant
of spontaneous as well as of treatment-induced clearance from
HCV infection [11,13]. The minor allele of IL28B (e. g.
rs12979860 T allele) has a an adverse effect on both spontaneous
and treatment-induced clearance, and it was shown that for
example the adverse IL28B rs12979860 CT/TT genotype is one
of the strongest baseline predictors of treatment failure [14].
Recently, vitamin D insufficiency (defined by a 25-hydroxyvi-
tamin D [25(OH)D3] serum concentration ,20 ng/mL) has been
proposed as a predictor of failure of treatment of chronic hepatitis
C with PEG-IFN-a and ribavirin [16,17]. Moreover, severe
vitamin D deficiency is a common feature of chronic hepatitis C,
even in the absence of advanced liver fibrosis [18]. These findings
may have important implications for the management of chronic
hepatitis C, as vitamin D status is a potentially modifiable
determinant of treatment outcome. However, it is currently
unknown whether vitamin D itself affects response to IFN-a-based
therapy or whether it is only a surrogate marker of treatment
outcome.
A number of genetic polymorphisms in the vitamin D pathway
have been shown to affect vitamin D signaling, and stratification
according to such polymorphisms has already being implemented
in randomized controlled clinical intervention studies [19–22].
Therefore, we believe that analyzing the impact of functionally
relevant genetic polymorphisms in the vitamin D cascade on SVR
may provide stronger evidence on an intrinsic role of vitamin D
metabolism in the pathogenesis and treatment of chronic hepatitis
C than analyzing exclusively vitamin D serum levels, which are
affected by various parameters, including season, sunlight expo-
sure, nutrition, and the metabolic syndrome [23,24]. Recently,
some of us have observed an association of the 1a-hydroxylase
promoter polymorphism CYP27B1-1260 rs10877012 with SVR in
a relatively small group of patients (n=110) [18]. In the present
study, we aimed to validate this association in 701 patients selected
from a well-characterized patient cohort, the Swiss Hepatitis C
Cohort Study (SCCS). In addition, we further characterized the
relationship between 25(OH)D3 serum levels and chronic hepatitis
C as well as its treatment.
Methods
Objectives
The primary objective of the present study was to evaluate
whether CYP27B1-1260 rs10877012 genotype, a genetic marker of
biologically active vitamin D, is associated with outcome of IFN-a
based therapy of chronic hepatitis C. Secondary objectives were to
characterize the frequency and determinants of vitamin D
deficiency in patients with chronic hepatitis C, and whether
serum levels of the calcitriol precursor 25(OH)D3 are suitable for
the prediction of treatment outcome as well.
Participants
Patients were followed within the framework of the SCCS, a
multicenter study pursued at 8 major Swiss hospitals and their
local affiliated centers, including a total of 3,648 patients with
chronic or resolved HCV infection [25]. For the present
retrospective analysis, two primary variables were analyzed:
outcome of treatment with PEG-IFN-a and ribavirin (SVR vs.
failure to achieve SVR) and 25(OH)D3 serum concentration (as
continuous variable). Patients were included in the analysis of
treatment response if they had treatment-naı ¨ve chronic hepatitis
C, had provided written informed consent for genetic testing, had
genomic DNA available for testing, were treated under clinical
practice conditions with either PEG-IFN-a2a or PEG-IFN-a2b in
combination with weight-based ribavirin, with standard treatment
durations (48 weeks for HCV genotype 1 and 4, 24 weeks for
HCV genotype 2 and 3), and if they had received $80% of the
recommended dose of both agents during the first 12 weeks of
therapy. Patients who received antiviral therapy not according to
these pre-defined criteria were excluded from the analyses. Serum
concentrations of 25(OH)D3 were determined in all patients in
whom a plasma sample at baseline of antiviral therapy was
available. Moreover, 25(OH)D3 serum levels were determined in
additional patients from the SCCS in whom a plasma sample at
the time of a liver biopsy was available.
Demographic and clinical characteristics including age, sex,
HCV genotype, HCV viral load, histological grade and stage,
alanine aminotransferase (ALT) serum levels, chronic hepatitis C
treatment, alcohol consumption, body mass index (BMI), and
presence or absence of diabetes were extracted from the SCCS
database. SVR was defined as HCV RNA below the limit of
detection in a sensitive assay $24 weeks after treatment
completion, and all patients who failed to achieve SVR were
classified as nonresponders. Data on rapid, early, and end-of-
treatment virologic response were not available. High alcohol
intake was defined as consumption .40 g per day over a period of
$5 years. Liver biopsies were evaluated by experienced local
pathologists. Liver fibrosis was classified according to the
METAVIR score. Necroinflammatory activity was stratified into
two groups, absent to mild activity vs. moderate to high activity.
Steatosis was classified as absent or present.
Description of Investigations Undertaken
Serum levels of 25(OH)D3 were measured as described
previously [18]. Concentrations ,20 ng/mL and ,10 ng/mL
were defined as vitamin D insufficiency and deficiency, respec-
tively, whereas concentrations $20 ng/mL were considered as
normal [24].
Genotyping for the CYP27B1-1260 rs10877012 single nucleo-
tide polymorphism (SNP) was performed using a TaqMan SNP
Genotyping Assay (Applied Biosystems, Foster City, CA) and the
ABI 7500 Fast Real-Time thermocycler, according to manufac-
turer’s recommendations. TaqMan probes and primers were
designed and synthesized by Applied Biosystems: rs10877012
forward 59-AACAGAGAGAGGGCCTGTCT-39, reverse 59-
GGGAGTAAGGAGCAGAGAGGTAAA-39, Vic probe 59-
CTGTGGGAGATTCTTTTAT-39, Fam probe 59-TGTGGGA-
GATTATTTTAT-39. Automated allele calling was performed
using SDS Software from Applied Biosystems. Positive and
negative controls were used in each genotyping assay. IL28B
rs12979860 genotyping was performed as described [26].
Ethics
The study was approved by local ethical committees of each
hospital (Universita ¨tsspital Basel, Basel; Inselspital, Bern; Univer-
sity Hospital Geneva, Geneva; CHUV, Lausanne; Ospedale
Moncucco, Lugano; Ho ˆpital Neucha ˆtelois, Neuchatel; Kantons-
spital St. Gallen, St. Gallen; Universita ¨tsspital Zu ¨rich, Zu ¨rich), and
written informed consent was received from all participants.
Statistical Analyses
Testing for Hardy-Weinberg equilibrium was performed with
the genhw package in Stata (version 9.1, StataCorp, College
Vitamin D and HCV Infection
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with dichotomic variables (SVR vs. nonresponse) were assessed in
logistic regression models. After univariate analyses, multivariate
analyses were performed for significant associations. Multivariate
models were obtained by backward selection, using a P value
.0.15 for removal from the model. Sex, age, and CYP27B1-1260
rs10877012 genotype were forced into the model. Only patients
with complete data for the remaining covariates were included in
multivariate analyses. SNPs were analyzed using an additive
model (none, one or two copies of the minor allele were coded 0, 1
and 2, respectively, assuming greater effect with increased copy
number of the minor allele), unless otherwise specified. Group
differences (e.g. CYP27B1-1260 rs10877012 AA vs.A Cvs. CC)
Table 1. Baseline and demographic characteristics.
Response to therapy
SVR (n=449) Non-Response (n=252)
25(OH)D3 serum concentration
(n=496)
Sex
Male, n (%) 276 (61) 170 (67) 314 (63)
Missing, n 0 0 0
Age, years
Mean (range) 44 (23–78) 46 (21–70) 45 (21–76)
Missing, n 79 53 73
HCV genotype, n (%)
1 140 (31) 170 (68) 203 (47)
2 70 (16) 11 (4) 44 (10)
3 206 (46) 43 (17) 148 (34)
4 32 (7) 26 (10) 41 (9)
Missing 1 2 60
Diabetes, n (%)
Yes 26 (6) 26 (10) 32 (6)
Missing 0 0 0
HCV RNA, log10 IU/mL
Mean (range) 5.77 (1–8) 5.00 (1–8) 5.66 (1–8)
Missing, n 0 0 3
Fibrosis stage, n (%)
0 27 (9) 12 (7) 31 (10)
1 7 7 ( 2 6 )3 1 ( 1 8 )9 5 ( 3 1 )
2 9 9 ( 3 3 )5 8 ( 3 4 )7 9 ( 2 6 )
3 3 6 ( 1 2 )3 3 ( 1 9 )4 4 ( 1 5 )
4 5 7 ( 1 9 )3 8 ( 2 2 )5 4 ( 1 8 )
Missing 153 80 193
Steatosis, n (%)
Yes 221 (72) 122 (76) 208 (73)
Missing, n 144 91 210
Activity, n (%)
None-mild 227 (77) 137 (79) 237 (78)
Moderate-high 67 (23) 36 (21) 66 (22)
Missing, n 155 79 193
BMI, kg/m
2
Mean (range) 24 (16–42) 25 (18–40) 24 (16–40)
Missing, n 106 70 171
ALT, U/L
Mean (range) 94 (8–693) 107 (18–617) 121 (8–720)
Missing, n 106 70 171
Univariate P values for SVR vs. nonresponse are shown in Table 2. ALT, alanine aminotransferase; BMI, body mass index; HCV, hepatitis C virus; SVR, sustained virologic
response. Of the 496 patients in whom 25(OH)D3 serum concentrations were measured, 269 were subsequently treated with pegylated interferon-a and ribavirin and
assessed for treatment outcome.
doi:10.1371/journal.pone.0040159.t001
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2 contingency tables or Wilcoxon-
Mann-Whitney-U-tests, as appropriate.
Results
Patient Characteristics
Out of a total of 3,648 patients enrolled in the SCCS, 701
patients were included in the analysis of treatment response based
on the selection criteria defined above. Of these, 269 patients had
a plasma sample at baseline of antiviral therapy available for
measurement of 25(OH)D3 level. Moreover, 25(OH)D3 serum
concentrations were determined in an additional 227 patients from
the SCCS in whom a plasma sample at the time of a liver biopsy
was available. Thus, 25(OH)D3 serum levels were determined in a
total of 496 patients. Epidemiological and clinical characteristics of
patients are summarized in Table 1.
CYP27B1-1260 rs10877012 and Response to Treatment of
Chronic Hepatitis C
The CYP27B1-1260 rs10877012 genotype was chosen as the
primary variable to be assessed for associations with treatment
outcome because this functional polymorphism in the promoter of
the 1a-hydroxylase affects tissue concentrations of calcitriol (the C
allele results in reduced calcitriol synthesis), thereby being a well-
characterized determinant of biologically active vitamin D [20,27].
rs10877012 genotype frequencies of the present cohort are shown
in Table 2. They were largely comparable to those previously
observed in the general population [18].
In a pooled analysis across all HCV genotypes, there was a
progressive decrease in SVR rates according to CYP27B1-1260
rs10877012 genotype (73% SVR for genotype AA, 65% for AC
and 62% for CC), suggesting an additive effect of the SNP.
However, the association was not significant (P=0.11, OR=1.22,
95% CI=0.954–1.552). Significance level increased in a multi-
variate model, after adjustment for HCV genotype, age, sex,
baseline viral load, BMI, ALT, diabetes, and IL28B rs12979860
genotype (P=0.06, OR=1.33, CI=0.988–1.796, Table 3) or
when comparing rs10877012 CC carriers to AA carriers
(P=0.04). When the association of CYP27B1-1260 rs10877012
with SVR was examined in patients stratified according to IL28B
Table 2. Genotype frequencies of the 1a-hydroxylase
promoter polymorphism CYP27B1-1260 rs10877012
in patients who received treatment with pegylated interferon-
a and ribavirin.
All, n (%)* HCV gt 1/4, n (%) HCV gt 2/3, n (%)
AA 63 (9) 34 (9) 29 (9)
CA 293 (42) 153 (42) 139 (42)
CC 345 (49) 181 (49) 162 (49)
The distribution of homozygous and heterozygous carriers corresponded to the
expectations from the Hardy-Weinberg equilibrium (P=0.35).
*This includes 3 patients with unknown HCV genotype. gt, genotype; HCV,
hepatitis C virus.
doi:10.1371/journal.pone.0040159.t002
Table 3. Factors associated with sustained virologic response.
Variable P value, univariate P value, multivariate Odds ratio (95% CI), multivariate
Age (years, continuous) ,0.001 ,0.001 0.96 (0.94–0.98)
HCV RNA (log10 IU/mL, continuous) ,0.001 ,0.001 0.38 (0.29–0.50)
ALT (U/L, continuous) 0.05
BMI (kg/m
2, continuous) 0.08
Male sex 0.10 1.0 0.85 (0.57–1.28)
HCV genotype 2/3 vs. 1/4 ,0.001 ,0.001 8.99 (4.21–19.19)
Diabetes 0.03
Fibrosis, F0–F1 vs. F2–F4 0.03
Steatosis 0.47
Necroinflammatory activity 0.71
Alcohol (40 g/d $5 years) 0.28
IL28B rs12979860 ,0.001 ,0.001 0.27 (0.17–0.43)
CYP27B1 rs10877012 0.11 0.06 1.33 (0.99–1.80)
ALT, alanine aminotransferase; BMI, body mass index; CI, confidence interval; HCV, hepatitis C virus.
doi:10.1371/journal.pone.0040159.t003
Figure 1. Treatment response according to CYP27B1-1260
rs10877012 genotype. Overall sustained virologic response (SVR)
rates across all HCV genotypes are shown for patients (A) with IL28B
rs12979860 genotype CC and for (B) patients with IL28B rs12979860
genotype CT or TT. Numbers above bars indicate SVR rates in percent.
Numbers below bars indicate absolute numbers of patients with SVR/all
patients.
doi:10.1371/journal.pone.0040159.g001
Vitamin D and HCV Infection
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CYP27B1-1260 rs10877012 was an independent predictor of SVR
in patients with the poor-response genotype CT or TT (65% vs.
57% vs. 51% SVR in CYP27B1-1260 rs10877012 AA vs.A Cvs.
CC, respectively; univariate P=0.06; multivariate P=0.02,
OR=1.52, 95% CI=1.061–2.188, Table 4) but not in those
with the good-response genotype CC (P=0.8).
A similar impact of CYP27B1-1260 rs10877012 on SVR was
observed when patients infected with genotype 1 and 4 were
analysed exclusively. Again, CYP27B1-1260 rs10877012 genotype
had no significant influence on SVR in patients with good-
response IL28B rs12979860 genotype (SVR rates 88% vs. 65% vs.
73% for AA vs.C Avs. CC, respectively; P=0.62). However, SVR
rates in HCV genotype 1 and 4 patients with poor-response IL28B
rs12979860 genotype were 42% vs. 39% vs. 30% in CYP27B1-
1260 rs10877012 AA vs.A Cvs. CC, respectively (univariate
P=0.11; multivariate P=0.09, OR=1.46, 95% CI=0.940–
2.288), but the association formally lost statistical significance,
most likely due to the low number (n=24) of HCV genotype 1 and
4 patients with CYP27B1-1260 rs10877012 AA and poor-response
IL28B rs12979860 genotype. With respect to the low frequency of
the beneficial minor A allele, CYP27B1-1260 rs10877012 does not
appear to be a suitable parameter for clinical decision making.
Nevertheless, our genetic analyses point to a relevant role of
vitamin D metabolism in the response to treatment with PEG-
IFN-a and ribavirin of chronic hepatitis C.
Serum Concentrations of 25-hydroxyvitamin D in
Patients with Chronic Hepatitis C
Serum concentrations of 25(OH)D3 were determined in 496
patients at baseline of treatment with PEG-IFN-a and ribavirin
(n=269) or at the time of liver biopsy in patients who were not
treated (n=227). Mean and median 25(OH)D3 serum concentra-
tions were 15.6 and 13.4 ng/mL (SD=9.07; range 3.8–76.9 ng/
mL), respectively, which are significantly lower than those
determined in the general population (e. g. 22.2 and 20 ng/mL
in Reusch et al., n.6.000) [24,28]. Among patients with chronic
hepatitis C, 32%, 42%, and 26% had 25(OH)D3 serum levels
,10, $10 to ,20, and $20 ng/mL, respectively. Because of the
seasonal fluctuation of 25(OH)D3 serum levels, we calculated
median 25(OH)D3 serum levels separately for each month.
Although season had a substantial impact on median 25(OH)D3
serum levels, at least 50% of HCV-infected individuals suffered
from vitamin D insufficiency (,20 ng/mL) even during summer,
while approximately 50% suffered from vitamin D deficiency
(,10 ng/mL) between November and April (Figure 2).
In a univariate analysis, age, male sex, infection with HCV
genotype 3, excessive alcohol consumption, presence of diabetes,
advanced liver fibrosis, and season of blood sampling were
significantly associated with low 25(OH)D3 serum levels (,
median; Table 5). In logistic regression analyses, age, advanced
liver fibrosis, presence of diabetes, and season of blood sampling
were independent and significant predictors of low 25(OH)D3
serum levels (Table 5).
Serum Concentrations of 25-hydroxyvitamin D and
Treatment Outcome
Since 25(OH)D3 serum concentrations were only available in a
subgroup of all treated patients included in this study (n=269), we
analyzed their relationship to treatment outcome separately from
the above-described CYP27B1 candidate gene study. In univariate
analyses, no significant associations between SVR and 25(OH)D3
serum levels either as continuous variable (p=0.13, OR=0.98,
95% CI=0.95–1.01), or 25(OH)D3 serum levels $10 ng/mL
(p=0.3, OR=0.74, 95% CI=0.43–1.30) and $20 ng/mL
Table 4. Factors associated with sustained virologic response in patients with unfavorable IL28B rs12979860 genotype CT or TT.
Variable P value, univariate P value, multivariate Odds ratio (95% CI), multivariate
Age (years, continuous) ,0.001 0.001 0.96 (0.94–0.98)
HCV RNA (log10 IU/mL, continuous) ,0.001 ,0.001 0.35 (0.25–0.50)
ALT (U/L, continuous) 0.10
BMI (kg/m
2, continuous) 0.16
Male sex 0.11 0.11 0.97 (0.59–1.60)
HCV genotype 2/3 vs.1/4 ,0.001 ,0.001 12.4 (5.01–30.9)
Diabetes 0.05
Fibrosis, F0–F1 vs. F2–F4 0.001
Steatosis 0.82
Necroinflammatory activity 0.86
Alcohol (.40 g/d $5 years) 0.30
CYP27B1 rs10877012 0.06 0.02 1.52 (1.06–2.19)
ALT, alanine aminotransferase; BMI, body mass index; CI, confidence interval; HCV, hepatitis C virus.
doi:10.1371/journal.pone.0040159.t004
Figure 2. Seasonal variation of 25(OH)D3 serum levels in
patients with chronic hepatitis C. Median 25(OH)D3 serum levels
are shown for each month.
doi:10.1371/journal.pone.0040159.g002
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mally, these associations may be even interpreted as a statistical
trend towards an inverse correlation between 25(OH)D3 serum
levels and SVR after treatment with PEG-IFN-a and ribavirin.
However, in multivariate models adjusted for other predictors of
treatment outcome (age, sex, IL28B rs12979860 genotype, HCV
genotype, HCV RNA levels, presence of diabetes, BMI, and liver
fibrosis), 25(OH)D3 serum levels were clearly not associated with
treatment outcome (p=0.9 for 25[OH]D3$20 ng/mL). These
findings were similar when HCV genotype 1/4 or 2/3 patients
were analyzed separately (data not shown).
Discussion
The results of the present genetic validation study suggest, in
line with our previously published findings [18], an association
between the CYP27B1-1260 promoter SNP rs10877012 and SVR
to treatment of chronic hepatitis C with PEG-IFN-a and ribavirin.
In the present study, this association was found only in patients
with a poor-response IL28B genetic background, whereas
CYP27B1-1260 rs10877012 was not significantly associated with
SVR in patients with good-response IL28B genotype. CYP27B1-
1260 rs10877012 is a functional polymorphism in the promotor of
the 1a-hydroxylase, the enzyme required for the bioactivation of
25(OH)D3 to 1,25(OH)2D3 (calcitriol) [20]. It has been shown that
the CC genotype of CYP27B1-1260 rs10877012 impairs the
expression of the 1a-hydroxylase, which results in reduced
concentrations of bioactive vitamin D [18,27]. Consistently, the
CC genotype of CYP27B1 is associated with poor response to
interferon-a-based treatment of chronic hepatitis C in the present
and in our previous study [18], as well as with the risk of bone
disease or autoimmune disorders such as multiple sclerosis or type
1 diabetes [19,20,27,29]. Importantly, 1a-hydroxylase is expressed
not only in the kidney but also in inflamed tissue and even in
immune cells, were it serves as a local, inducible producer of
calcitriol [30]. Bioactive vitamin D is an important immune
modulator, as for example T cells and macrophages crucially
depend on calcitriol in various conditions [31–33]. Thus, one may
speculate that the ‘‘poor-response’’ CYP27B1-1260 rs10877012
genotype CC may result in lower local concentrations of calcitriol
in the HCV-infected liver, resulting in reduced responsiveness to
IFN-a or impaired adaptive immune responses. This may be
especially relevant in patients with unfavourable IL28B genotype,
who in general poorly respond to IFN-a.
The present study confirms that patients with chronic hepatitis
C patients have a high prevalence of vitamin D insufficiency.
However, in our study, 25(OH)D3 serum levels were not
associated with treatment outcome in a subgroup of 269 patients
with available baseline serum samples before antiviral treatment.
In fact, 25(OH)D3 serum levels were even somewhat lower in
patients who subsequently achieved SVR as compared to those
who failed to respond to treatment. In two previous studies,
including 167 and 211 patients treated with IFN-a-based therapy,
a weak but significant correlation between 25(OH)D3 serum levels
and SVR was observed [16,34]. In our previous analysis we did
not observe any significant association between 25(OH)D3 serum
levels and SVR to IFN-a-based therapy in a cohort of 317 HCV
genotype 1-infected patients, but a significant association in a
cohort of 156 patients infected with genotype 2 or 3 [18]. Two
studies in HCV-HIV-coinfected patients found no correlation
between 25(OH)D3 serum levels and treatment outcome as well
[35,36]. The reasons for these discrepancies remain unclear at the
moment, but apparently 25(OH)D3 serum levels cannot be
considered as an established predictor of treatment outcome at
the moment.
Importantly, it is well-known that 25(OH)D3 serum levels
correlate poorly with calcitriol serum concentrations, and
25(OH)D3 serum levels are therefore not a suitable marker for
bioactive vitamin D or vitamin D receptor signaling, especially not
for local calcitriol levels during inflammatory conditions [24].
Thus, the lacking lack of an association between 25(OH)D3 serum
levels and SVR may simply reflect the limited biological relevance
of 25(OH)D3 serum levels. Unfortunately, there are no reliable
methods to quantify serum levels of the bioactive vitamin D
metabolite calcitriol, and the majority of clinical trials assessing the
vitamin D status of patients focus on the calcitriol precursor
25(OH)D3 [24]. Therefore, despite the lack of an association
Table 5. Factors associated with 25-hydroxyvitamin D serum levels ($ median) in patients with chronic hepatitis C.
Variable P value, univariate P value, multivariate Odds ratio (95% CI), multivariate
Age (years, continuous) 0.2 0.013 1.06 (1.01–1.12)
HCV RNA (log10 IU/mL, continuous) 0.3
ALT (U/L, continuous) 0.6
BMI (kg/m
2, continuous) 0.4
IL28B rs12979860 0.3
Male sex 0.003 0.5 0.77 (0.33–1.80)
HCV genotype 1,2,4 vs.3
1 0.034
HIV coinfection 0.6
Diabetes 0.049 0.01 0.17 (0.04–0.66)
Alcohol (.40 g/d $5 years) 0.010
Fibrosis, F0–F1 vs. F2–F4 0.009 0.018 0.31 (0.12–0.82)
Necroinflammatory activity 0.9
Steatosis 0.07
Season of blood sampling ,0.0001 ,0.0001 6.49 (2.71–15.6)
1Genotype 1, 2 and 4 were grouped vs. genotype 3 in this analysis, as the latter has been associated with metabolic disturbances (insulin resistance, steatosis) and more
rapid fibrosis progression [37,38]. ALT, alanine aminotransferase; BMI, body mass index; CI, confidence interval; HCV, hepatitis C virus.
doi:10.1371/journal.pone.0040159.t005
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association between SVR and a functionally relevant genetic
polymorphism in the vitamin D cascade, CYP27B1-1260
rs10877012, suggests a role of vitamin D in the response to
treatment of chronic hepatitis C. In line with this notion, we have
recently identified an interaction between the vitamin D receptor
and IFN-a-induced signaling through the Jak-STAT pathway,
which results in a synergistic effect of calcitriol and INF-a on
interferon-stimulated gene expression as well as on HCV
replication in vitro (CML, MHH and DM, unpublished data).
Therefore, the question as to whether optimization of the patients’
vitamin D status may be beneficial before or during antiviral
therapy remains open.
In conclusion, the present study suggests a role of vitamin D
metabolism in the response to treatment of chronic hepatitis C,
especially in patients with poor-response IL28B genotype, but
importantly 25(OH)D3 serum levels are not a reliable marker of
treatment outcome.
Limitations
Several limitations of our study have to be acknowledged. First,
the association between CYP27B1-1260 rs10877012 and SVR is
statistically relatively weak, as it might be expected from the
moderate impact of this variation on calcitriol synthesis [20,27]. In
line with this notion, we did not observe any significant association
between CYP27B1-1260 genotype and acute clearance from HCV
infection in a cohort of 112 patients (data not shown). Therefore,
CYP27B1-1260 rs10877012 genotype does not appear to be a
suitable marker for clinical decision making, and even larger
sample sizes may be required to fully confirm the association
between CYP27B1 and SVR. Nevertheless, we believe that the
importance of this genetic validation study lies in the identification
of vitamin D signaling as an intrinsic player in IFN-a-based
therapy of chronic hepatitis C. Second, 25(OH)D3 serum levels
were available only for a subgroup of treated patients (n=269),
and significant associations might be identified in larger sample
sizes. Furthermore, we cannot exclude a possible selection bias due
the availability of serum in only a limited proportion of patients
included in the primary analysis of CYP27B1 genotype. Finally,
incomplete datasets in some of our patients may be an additional
source of bias, which represents a limitation inherent to cohort
studies as compared to randomized controlled trials.
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